Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis-Reference-Cited by-同舟云学术

Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis

Published:2022-09-20 Issue:11 Volume:4 Page:983-990
ISSN:2578-5745
Container-title:ACR Open Rheumatology
language:en
Short-container-title:ACR Open Rheumatology

Author:

Oddis Chester V.¹^ORCID,Rockette Howard E.¹,Zhu Lei¹^ORCID,Koontz Diane C.¹,Lacomis David¹,Venturupalli Swamy²,Moghadam‐Kia Siamak¹,Ascherman Dana P.¹^ORCID,Crofford Leslie³,Dimachkie Mazen M.⁴,Ernste Floranne⁵,Gazeley David⁶,Marder Galina⁷,Aggarwal Rohit¹

Affiliation:

1. University of Pittsburgh School of Medicine Pittsburgh Pennsylvania

2. Cedars Sinai Medical Center and University of California Los Angeles School of Medicine Los Angeles California

3. Vanderbilt University Medical Center Nashville Tennessee

4. University of Kansas Medical Center Kansas City

5. Mayo Clinic Rochester Minnesota

6. Medical College of Wisconsin Milwaukee

7. Hofstra Northwell School of Medicine Uniondale New York

Funder

Genentech

Publisher

Wiley

Subject

Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11493

Reference18 articles.

1. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial

2. 2016 American College of Rheumatology/European League against rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group/paediatric rheumatology international trials organisation collaborative initiative;Aggarwal R;Ann Rheum Dis,2017

3. Tocilizumab – A novel therapy for non-organ-specific autoimmune diseases

4. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

5. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel therapeutic targets in dermatomyositis;The Journal of Dermatology;2024-03-03

2. Where are we now in biologic drugs for myositis?;Rheumatology;2024-02-06

3. Effectiveness and safety of plasma exchange for anti‐MDA5 antibody–positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series;Therapeutic Apheresis and Dialysis;2024-01-15

4. Tocilizumab Treatment in a Patient of Refractory Anti-EJ Positive ASyS: A Case Report;Journal of Investigative Medicine High Impact Case Reports;2024-01

5. Idiopathic Inflammatory Myositis;Neuroimmune Diseases;2024